tiprankstipranks
Advertisement
Advertisement

RIGL Stock Latest News

Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler
The FlyRigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler
22d ago
RIGL
Rigel Pharmaceuticals’ Veppanu available for metastatic breast cancer
PremiumThe Fly
Rigel Pharmaceuticals’ Veppanu available for metastatic breast cancer
22d ago
RIGL
Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright
PremiumThe Fly
Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright
23d ago
RIGL
Rigel Pharmaceuticals price target raised to $83 from $81 at Citi
PremiumThe Fly
Rigel Pharmaceuticals price target raised to $83 from $81 at Citi
1M ago
RIGL
Rigel Pharmaceuticals Balances Growth with Rising Costs
PremiumCompany Announcements
Rigel Pharmaceuticals Balances Growth with Rising Costs
1M ago
RIGL
Rigel: Buy Rating Reaffirmed as Solid Commercial Performance and Pipeline Catalysts Support Unchanged $57 Price Target
PremiumRatingsRigel: Buy Rating Reaffirmed as Solid Commercial Performance and Pipeline Catalysts Support Unchanged $57 Price Target
1M ago
RIGL
Rigel Pharmaceuticals raises FY26 revenue view to $285M-$295M from $275M-$290M
Premium
The Fly
Rigel Pharmaceuticals raises FY26 revenue view to $285M-$295M from $275M-$290M
1M ago
RIGL
Rigel Pharmaceuticals reports Q2 EPS 88c, consensus (8c)
Premium
The Fly
Rigel Pharmaceuticals reports Q2 EPS 88c, consensus (8c)
1M ago
RIGL
RIGL Earnings this Week: How Will it Perform?
PremiumPre-Earnings
RIGL Earnings this Week: How Will it Perform?
1M ago
RIGL
Rigel Appoints Alison Hannah as New Chief Medical Officer
PremiumCompany Announcements
Rigel Appoints Alison Hannah as New Chief Medical Officer
2M ago
8K
RIGL
Rigel appoints Alison Hannah as Chief Medical Officer and Vice President
PremiumThe Fly
Rigel appoints Alison Hannah as Chief Medical Officer and Vice President
2M ago
RIGL
Rigel Expands Oncology Portfolio with VEPPANU Global Rights
PremiumCompany Announcements
Rigel Expands Oncology Portfolio with VEPPANU Global Rights
3M ago
8K
RIGL
Rigel closes license agreement for Veppanu
PremiumThe FlyRigel closes license agreement for Veppanu
3M ago
PFE
ARVN
Pantginis Reiterates Buy on Rigel, Citing Strengthening Oncology Portfolio and Unchanged $57 Price Target
Premium
Ratings
Pantginis Reiterates Buy on Rigel, Citing Strengthening Oncology Portfolio and Unchanged $57 Price Target
3M ago
RIGL
Rigel partner Kissei submits new drug application for olutasidenib in Japan
Premium
The Fly
Rigel partner Kissei submits new drug application for olutasidenib in Japan
3M ago
RIGL
H.C. Wainwright highlights Rezlidhia NDA as expanding Rigel’s ex-U.S. reach
PremiumThe Fly
H.C. Wainwright highlights Rezlidhia NDA as expanding Rigel’s ex-U.S. reach
3M ago
RIGL
Lilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches Completion
PremiumCompany Announcements
Lilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches Completion
4M ago
LLY
RIGL
Rigel: Buy Rating Reiterated as New Oncology Data Support Franchise Strength and Unchanged $57 Price Target
PremiumRatings
Rigel: Buy Rating Reiterated as New Oncology Data Support Franchise Strength and Unchanged $57 Price Target
4M ago
RIGL
Rigel Shareholders Approve Equity Plans and Board Slate
PremiumCompany Announcements
Rigel Shareholders Approve Equity Plans and Board Slate
4M ago
8K
RIGL
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs
PremiumCompany AnnouncementsRigel Pharmaceuticals Highlights Growth Amid Rising Costs
4M ago
RIGL
Arvinas price target raised to $16 from $14 at BofA
Premium
The Fly
Arvinas price target raised to $16 from $14 at BofA
4M ago
PFE
ARVN
Arvinas price target raised to $18 from $16 at BTIG
Premium
The Fly
Arvinas price target raised to $18 from $16 at BTIG
4M ago
ARVN
RIGL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >